PTPN22 and inflammatory bowel disease: After Bonferroni correction for multiple testing both the homozygous and the heterozygous variant genotypes of IL23R G>A (rs11209026) (ORadj: 0.43, 95% CI: 0.28–0.67, p = 0.007) and PTPN22 1858 G>A (rs2476601) (ORunadj: 0.61, 95% CI: 0.48–0.77, p = 0.001) were associated with reduced risk of IBD.